+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hemophilia Treatment Market by Therapeutic Class, Treatment Mode, End User, Distribution Channel - Global Forecast to 2030- Product Image
Hemophilia Treatment Market by Therapeutic Class, Treatment Mode, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Hemophilia Treatment Market by Therapeutic Class, Treatment Mode, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 196 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4829909
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The hemophilia treatment market is entering a dynamic era, shaped by rapid biomedical innovation, digital health adoption, and evolving global care paradigms. Senior leaders now face increasingly complex decisions amid ongoing consolidation, technology advancements, and mounting demands for clinical, operational, and economic efficiency.

Market Snapshot: Hemophilia Treatment Market Overview

The Hemophilia Treatment Market grew from USD 15.23 billion in 2024 to USD 16.26 billion in 2025. It is expected to continue growing at a CAGR of 6.47%, reaching USD 22.19 billion by 2030. This growth reflects heightened demand for next-generation gene therapies, novel replacement treatments, and value-driven solutions that improve patient outcomes while streamlining long-term care expenditures. The rising uptake of technologies supporting home-based and proactive management is accelerating a transition from traditional hospital-centric models to more adaptive frameworks involving integrated providers, payers, and specialty suppliers.

Scope & Segmentation

This report provides a detailed analysis and forecast of the hemophilia treatment market, focusing on critical segments and underlying technologies that are transforming care delivery and access.

  • Therapeutic Class: Covers gene therapy and replacement therapy, assessing advancements and the balance between curative potential and established clinical practice.
  • Treatment Mode: Explores on-demand and prophylaxis regimens, highlighting shifting protocols and patient preference trends.
  • End User: Includes home healthcare, hospitals, and specialized clinics, providing insights into evolving care delivery sites and patient autonomy.
  • Distribution Channel: Considers hospital and retail pharmacy models, evaluating direct-to-patient and clinical distribution routes.
  • Geographies: Analyzes the Americas, Europe, Middle East & Africa, and Asia-Pacific, with country-level assessments including the United States, Canada, Germany, China, Japan, and other major markets.
  • Leading Companies: Examines strategy and innovation from Roche Holding AG, Takeda, Swedish Orphan Biovitrium AB, Bayer AG, CSL Limited, Novo Nordisk, Pfizer Inc., Octapharma AG, Grifols, and BioMarin.

Key Takeaways for Senior Decision-Makers

  • Innovation in gene therapy and advanced replacement products is reshaping clinical expectations, creating both disruption and new value opportunities for incumbents and emerging firms.
  • Digital health tools—including wearables and remote monitoring platforms—are boosting patient adherence, enabling proactive management, and supporting real-world data generation.
  • Market access strategies must address varying regional reimbursement requirements, infrastructure capabilities, and patient support frameworks to drive adoption and optimize resource allocation.
  • Value-based contracting is gaining traction, necessitating robust outcome tracking and collaborative payer-manufacturer models that align incentives for quality and affordability.
  • The interplay between home-based care and hospital-based interventions demands hybrid service models that integrate multidisciplinary expertise and patient education programs.

Tariff Impact: Navigating U.S. Policy Shifts

The 2025 introduction of United States import tariffs has intensified cost pressures for manufacturers, distributors, and providers across the supply chain. Higher duties on specialized equipment and raw materials are prompting industry participants to renegotiate supplier contracts, adjust procurement practices, and tailor pricing strategies to offset increased expenditures. Health insurers and public payers have begun to recalibrate reimbursement policies, adding new utilization reviews and stricter formulary controls. These changes highlight the need for ongoing vigilance to policy developments and collaborative solutions to sustain patient access and supplier innovation.

Methodology & Data Sources

This analysis is grounded in primary and secondary research, combining literature reviews with expert interviews across hematology, health economics, payer relations, and advocacy. Data integrity is reinforced through triangulation, proprietary clinical trial tracking, and rigorous multi-stage verification, ensuring relevance and actionable insights for business planning.

Why This Report Matters

  • Provides actionable intelligence to guide investment, partnership, and channel strategies amid shifting therapeutic, technology, and policy landscapes.
  • Equips leadership teams with structured frameworks to de-risk regional expansion, optimize supply chains, and align product portfolios with emerging clinical and market needs.

Conclusion

Stakeholders equipped with this comprehensive analysis can more confidently navigate hemophilia market evolution, adapt to regulatory and economic headwinds, and capture growth by aligning innovation with operational resilience and patient-centric outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Hemophilia Treatment Market, by Therapeutic Class
8.1. Introduction
8.2. Gene Therapy
8.3. Replacement Therapy
9. Hemophilia Treatment Market, by Treatment Mode
9.1. Introduction
9.2. on-Demand
9.3. Prophylaxis
10. Hemophilia Treatment Market, by End User
10.1. Introduction
10.2. Home Healthcare
10.3. Hospitals
10.4. Specialized Clinics
11. Hemophilia Treatment Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Retail Pharmacy
12. Americas Hemophilia Treatment Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Hemophilia Treatment Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Hemophilia Treatment Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Roche Holding AG
15.3.2. Takeda Pharmaceutical Company Limited
15.3.3. Swedish Orphan Biovitrium AB
15.3.4. Bayer AG
15.3.5. CSL Limited
15.3.6. Novo Nordisk a/S
15.3.7. Pfizer Inc.
15.3.8. Octapharma AG
15.3.9. Grifols, S.A.
15.3.10. BioMarin Pharmaceutical Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. HEMOPHILIA TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. HEMOPHILIA TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. HEMOPHILIA TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. HEMOPHILIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. HEMOPHILIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. HEMOPHILIA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY ON-DEMAND, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 24. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 25. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 26. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 27. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 28. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 29. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 30. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 31. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 32. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 34. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 35. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 36. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 46. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 47. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 50. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 51. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 52. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 55. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 56. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 59. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 60. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 61. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 62. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 63. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 64. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 66. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 67. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 68. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 71. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 72. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. UNITED ARAB EMIRATES HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 75. UNITED ARAB EMIRATES HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 76. UNITED ARAB EMIRATES HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. UNITED ARAB EMIRATES HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. SAUDI ARABIA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 79. SAUDI ARABIA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 80. SAUDI ARABIA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. SAUDI ARABIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. SOUTH AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 83. SOUTH AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 84. SOUTH AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. SOUTH AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. DENMARK HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 87. DENMARK HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 88. DENMARK HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. DENMARK HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. NETHERLANDS HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 91. NETHERLANDS HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 92. NETHERLANDS HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. NETHERLANDS HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. QATAR HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 95. QATAR HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 96. QATAR HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. QATAR HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. FINLAND HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 99. FINLAND HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 100. FINLAND HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. FINLAND HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. SWEDEN HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 103. SWEDEN HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 104. SWEDEN HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. SWEDEN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 108. NIGERIA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. NIGERIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. EGYPT HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 111. EGYPT HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 112. EGYPT HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. EGYPT HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. TURKEY HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 115. TURKEY HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 116. TURKEY HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. TURKEY HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. ISRAEL HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 119. ISRAEL HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 120. ISRAEL HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. ISRAEL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. NORWAY HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 123. NORWAY HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 124. NORWAY HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. NORWAY HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. POLAND HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 127. POLAND HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 128. POLAND HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. POLAND HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. SWITZERLAND HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 131. SWITZERLAND HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 132. SWITZERLAND HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 135. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 136. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 139. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 140. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 141. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 143. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 144. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 145. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 148. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 149. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 150. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 151. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 152. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 153. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 156. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 157. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. INDONESIA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 160. INDONESIA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 161. INDONESIA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. INDONESIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. THAILAND HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 164. THAILAND HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 165. THAILAND HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. THAILAND HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. PHILIPPINES HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 168. PHILIPPINES HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 169. PHILIPPINES HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. PHILIPPINES HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. MALAYSIA HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 172. MALAYSIA HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 173. MALAYSIA HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. MALAYSIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. SINGAPORE HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 176. SINGAPORE HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 177. SINGAPORE HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. SINGAPORE HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. VIETNAM HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 180. VIETNAM HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 181. VIETNAM HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. VIETNAM HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. TAIWAN HEMOPHILIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 184. TAIWAN HEMOPHILIA TREATMENT MARKET SIZE, BY TREATMENT MODE, 2018-2030 (USD MILLION)
TABLE 185. TAIWAN HEMOPHILIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. TAIWAN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. HEMOPHILIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
TABLE 188. HEMOPHILIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Hemophilia Treatment market report include:
  • Roche Holding AG
  • Takeda Pharmaceutical Company Limited
  • Swedish Orphan Biovitrium AB
  • Bayer AG
  • CSL Limited
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Octapharma AG
  • Grifols, S.A.
  • BioMarin Pharmaceutical Inc.

Table Information

Report AttributeDetails
No. of Pages196
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 16.26 Billion
Forecasted Market Value ( USD ) by 2030 $ 22.19 Billion
Compound Annual Growth Rate6.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Hemophilia Treatment - Global Strategic Business Report - Product Image

Hemophilia Treatment - Global Strategic Business Report

  • Report
  • 476 Pages
  • Global
From
Hemophilia Drugs - Global Strategic Business Report - Product Image

Hemophilia Drugs - Global Strategic Business Report

  • Report
  • 182 Pages
  • Global
From
Hemophilia A Treatment Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F - Product Image

Hemophilia A Treatment Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F

  • Report
  • 186 Pages
  • Global
From
Acquired Hemophilia Treatment Market Report 2025 - Product Image

Acquired Hemophilia Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Hemophilia Market Report by Type, Treatment, Therapy, and Region 2024-2032 - Product Image

Hemophilia Market Report by Type, Treatment, Therapy, and Region 2024-2032

  • Report
  • 135 Pages
  • Global
From

About the Hemophilia Drug Market

The Hemophilia Drug market is a subset of the larger Hematological Drugs market. Hemophilia drugs are used to treat and prevent bleeding episodes in people with hemophilia, a rare genetic disorder. These drugs are typically administered intravenously or subcutaneously and are designed to replace the missing clotting factor in the patient's blood. Commonly used hemophilia drugs include recombinant factor VIII and IX, as well as plasma-derived factor VIII and IX. The Hemophilia Drug market is highly competitive, with a number of companies offering a variety of products. Some of the major players in the market include Pfizer, Novo Nordisk, Bayer, Biogen, CSL Behring, and Shire. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.